Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Aug 28, 2019	CareDx Acquires XynManagement Acquisition solidifies transplant leadership with transplant center quality management and patient waitlist management tools BRISBANE, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and	View HTML
Toggle Summary Aug 27, 2019	Chris Cournoyer Joins CareDx Board of Directors Cournoyer brings deep digital expertise to CareDx to support burgeoning digital solutions portfolio BRISBANE, Calif. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically	View HTML
Toggle Summary Aug 22, 2019	AlloSure for Heart Transplant Patients Receives CMS Draft Coverage CareDx expands leadership with cfDNA for transplant care BRISBANE, Calif. , Aug. 22, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions	View HTML
Toggle Summary Aug 21, 2019	Fear of Rejection is Transplant Patient’s Top Concern CareDx partnership with American Association of Kidney Patients yields key patient insights BRISBANE, Calif. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically	View HTML
Toggle Summary Aug 01, 2019	CareDx Reports Second Quarter 2019 Results AlloSure momentum drives 76% second quarter revenue growth BRISBANE, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare	View HTML
Toggle Summary Jul 16, 2019	CareDx to Announce Second Quarter 2019 Financial Results on August 1, 2019 BRISBANE, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Jul 11, 2019	CareDx Applauds White House Efforts to Reform America’s Kidney Health System Executive Order outlines initiatives to make organ transplantation the preferred treatment option BRISBANE, Calif. , July 11, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically	View HTML
Toggle Summary Jul 02, 2019	Grace Colón succeeds Amy Abernethy on the CareDx Board Colón brings expertise to grow patient centric innovation capabilities at CareDx BRISBANE, Calif. , July 02, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated,	View HTML
Toggle Summary Jun 27, 2019	CareDx Supports Momentum in Medicare Immunosuppressive Medication Legislation Kidney community rallies in support as introduction of the immunosuppression coverage bill is imminent BRISBANE, Calif. , June 27, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of	View HTML
Toggle Summary Jun 26, 2019	US Patent Office Issues New Transplant Patent to CareDx CareDx continues to lead innovation in transplantation BRISBANE, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic	View HTML